Reuters logo
2 months ago
BRIEF-ExpreS2ion Biotech holding unit accelerates development of therapeutic, prophylactic vaccines
June 28, 2017 / 5:13 AM / 2 months ago

BRIEF-ExpreS2ion Biotech holding unit accelerates development of therapeutic, prophylactic vaccines

June 28 (Reuters) - EXPRES2ION BIOTECH HOLDING AB

* SAYS THE FULLY OWNED SUBSIDIARY EXPRES2ION BIOTECHNOLOGIES APS THROUGH JOINT VENTURE HAS ACCELERATED DEVELOPMENT OF THERAPEUTIC AND PROPHYLACTIC VACCINES WITHIN SEGMENTS OF ONCOLOGY, INFECTIOUS DISEASES AND IMMUNOLOGICAL DISORDERS​

* ‍RISK-ADJUSTED NET PRESENT VALUE OF EXPRES2ION'S STAKE IN ADAPTVAC'S INITIAL PIPELINE IS ESTIMATED TO BE IN 50-100 MILLION SEK RANGE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below